Argipressin

DRUG2 trials

Sponsors

Kristina Svennerholm, Centre Hospitalier Universitaire Dijon

Conditions

Colon Cancer Liver MetastasisInflammatory ResponsePatients With Norepinephrine-refractory Vasoplegic ShockVasopressin Causing Adverse Effects in Therapeutic Use

Phase 3

Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

RecruitingNCT07063680

Centre Hospitalier Universitaire DijonPatients With Norepinephrine-refractory Vasoplegic Shock

Start: 2026-04-07End: 2029-01-01Target: 390Updated: 2026-04-14

Phase 4

Argipressin's Influence on Blood Loss During Hepatic Resection

CompletedNCT05293041

Kristina SvennerholmColon Cancer Liver Metastasis, Inflammatory Response, Vasopressin Causing Adverse Effects in Therapeutic Use

Start: 2022-03-27End: 2025-02-17Updated: 2025-03-06

Related Papers

Argipressin for prevention of blood loss in hepatic resection: a randomised, placebo-controlled, double-blind trial.

2025-10-30

Argipressin for prevention of blood loss during liver resection: a study protocol for a randomised, placebo-controlled, double-blinded trial (ARG-01)

BMJ Open2023-08-015 citations